ServicesProcessTestimonials
Book a call
Burger menu
ServiceProcessTestimonials
Book a call

SignalsΒ 

/

Biotech & Healthcare

πŸ§ͺ

Biotech & Healthcare

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
112
signals this month
β€’
28
sources monitored
β€’
Updated
2x daily
All
Regulatory
Ransomware
Funding
M&A
Product Launch
Layoffs
Legal
Date
Type
Signal
Sourse
Layoffs
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
Fierce Biotech
β†’
October 27, 2026
Layoffs
Artiva Biotherapeutics cuts 94% of workforce after patient deaths, ends lead program
BioSpace
β†’
IPO
Aspen Neuroscience and Bambusa Therapeutics each file for ~$134M IPOs
Fierce Biotech
β†’
Layoffs
Tango Therapeutics cuts 14% workforce, deprioritizes discovery to focus on key candidates
Fierce Biotech
β†’
IPO
Lycia Therapeutics completes upsized $317.5M Nasdaq IPO; Windward Bio files for listing
Fierce Biotech
β†’
September 11, 2026
Funding
Novo Holdings and international funds invest nearly DKK 60m in new Danish biotech CaMaRa
medwatch.com
β†’
September 14, 2026
Funding
Connecta Therapeutics raises $3.5M for Fragile X syndrome Phase IIa trial
BioXconomy
β†’
September 21, 2026
Funding
Novadip Biosciences raises €10.4M convertible financing for pivotal Phase 3 trial
EU-Startups
β†’
September 7, 2026
Funding
Superluminal raises $60M Series B for obesity drug
BioXconomy
β†’
M&A
EQT acquires molecular diagnostics company Qiagen in €10.8B deal
Fierce Biotech
β†’
M&A
Hologic acquires Reveal Genomics to expand genomic diagnostic reach
Fierce Biotech
β†’
M&A
Gilead pays $1.3B upfront for PepStar's oral IL-23 inhibitor program HCXT-2001
Fierce Biotech
β†’
October 19, 2026
Layoffs
EyePoint to halve workforce, end pivotal wet AMD trials early after second Phase 3 fail
BioSpace
β†’
October 20, 2026
M&A
Noucor completes acquisition of Helm Pharmaceuticals to build European pharma platform
Investors in Healthcare
β†’
October 21, 2026
Regulatory
GSK receives FDA nod for hepatitis B drug Hibsago (bepirovirsen)
Fierce Pharma
β†’
IPO
Rezera (formerly NodThera) files for IPO to fund NLRP3 inhibitor ruvonoflast Phase 3
Fierce Biotech
β†’
Layoffs
Enlivex lays off 60% of staff, scraps preclinical R&D, cuts exec salaries to fund phase 2b
Fierce Biotech
β†’
M&A
Labcorp acquires BioReference Health assets for $722M cash
Fierce Biotech
β†’
M&A
Myriad Genetics sells Prenatal Health testing business to Labcorp for $210M
Fierce Biotech
β†’
M&A
Ambrose Healthcare acquires AM-Pharma for up to $181M
Fierce Biotech
β†’
October 20, 2026
M&A
Ambrose Healthcare acquires AM-Pharma for up to €161M, gaining European base
Dealroom
β†’
IPO
Lycia Therapeutics targets $228M IPO to fund protein degrader pipeline for food allergy
Fierce Biotech
β†’
IPO
TCGX SPAC to take migraine biotech TriGemX Bio public with ~$246M proceeds
Fierce Biotech
β†’
October 19, 2026
M&A
Merck KGaA to acquire UK biotech Silence Therapeutics in $1.3bn RNA deal
Manufacturing Chemist
β†’
M&A
Merck KGaA acquires Silence Therapeutics in $1.3B siRNA blood cancer deal
Fierce Biotech
β†’
August 28, 2026
Funding
AusperBio raises $120M Series C to advance hep B oligo therapy through phase 3
Fierce Biotech
β†’
September 8, 2026
Funding
Moonwalk Biosciences Raises $70M Series B for RNAi Obesity Therapies
genengnews.com
β†’
October 18, 2026
M&A
Mankind Pharma acquires 70% stake in Belgium CAR-T biotech ACTx for €48M
www.nationpathindia.com
β†’
M&A
Roche licenses Rona Therapeutics' ALK7 obesity candidate in $1.2B deal
Fierce Biotech
β†’
Expansion
Zealand Pharma inks $1.2B Generate Biomedicines pact for multispecific obesity proteins
Fierce Biotech
β†’
October 12, 2026
M&A
STERIS agrees to acquire surgical safety firm Xodus Medical for $2.1B
RAPS
β†’
October 14, 2026
Layoffs
GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam
Fierce Biotech
β†’
Regulatory
SimBioSys receives FDA clearance for AI-powered breast cancer recurrence risk tool
Fierce Biotech
β†’
IPO
City Therapeutics goes public with upsized $200M IPO on Nasdaq
Fierce Biotech
β†’
October 14, 2026
Regulatory
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive NMIBC
Oncology Nursing News
β†’
IPO
Iambic Therapeutics raises $150M IPO to fund oncology pipeline and AI drug discovery platform
Fierce Biotech
β†’
M&A
Agilent acquires digital pathology software company Proscia for $240M
Fierce Biotech
β†’
October 14, 2026
Layoffs
GSK plans 1,200+ layoffs at Belgium sites as $2.5B restructure gains momentum
BioSpace
β†’
October 15, 2026
IPO
Iambic Therapeutics raises $150M in IPO for AI drug discovery platform
BioPharma Dive
β†’
October 12, 2026
Regulatory
FDA Approves Teva's Once-Monthly Subcutaneous Olanzapine (Weltruza) for Schizophrenia
Drug Topics
β†’
Regulatory
FDA clears Aptitude's Metrix molecular COVID diagnostic with 510(k)
Fierce Biotech
β†’
October 12, 2026
Expansion
GSK pledges $800M to add biologics production capabilities in Pennsylvania
BioSpace
β†’
Regulatory
VertigoDx receives FDA 510(k) clearance for SmartVertigo diagnostic system
Fierce Biotech
β†’
Expansion
AstraZeneca opens new Kendall Square R&D center in Cambridge, MA
Fierce Biotech
β†’
M&A
Novartis pays $575M upfront for Abogen's mRNA T-cell engager ABO2203
Fierce Biotech
β†’
IPO
AI biotech Iambic aims for $135M IPO to fund cancer drug clinical development
Fierce Biotech
β†’
IPO
TRex Bio raises $117M IPO; Retension Pharmaceuticals lists with $45M IPO
Fierce Biotech
β†’
IPO
Aspen Neuroscience and Bambusa Therapeutics file for IPOs
Fierce Biotech
β†’
October 8, 2026
M&A
Ofichem acquires US CDMO Kinentia Biosciences to expand transatlantic network
Manufacturing Chemist
β†’
October 8, 2026
M&A
Viatris to acquire Pacira BioSciences for $1.65B
Fierce Pharma
β†’
October 9, 2026
IPO
TRex Bio prices $117M IPO to support immune drug development
BioPharma Dive
β†’
Regulatory
FDA approves Edwards Lifesciences' Autus Size-Adjustable pediatric heart valve
Fierce Biotech
β†’
Layoffs
Enanta Pharmaceuticals lays off 37 employees ahead of key antiviral and immunology readouts
Fierce Biotech
β†’
September 28, 2026
Regulatory
FDA approves Mirum's oral drug Atebrioz for rare disease FOP
pharmaphorum
β†’
September 28, 2026
Regulatory
FDA approves Biofrontera's Ameluz for superficial basal cell carcinoma
Geisel School of Medicine at Dartmouth
β†’
October 7, 2026
Regulatory
FDA Grants 510(k) Clearance to Click Therapeutics' Motivista for Schizophrenia
Psychiatric Times
β†’
October 6, 2026
Regulatory
FDA approves AbbVie's Parkinson's drug Juvmo (tavapadon) developed from UVA research
WSET
β†’
October 6, 2026
M&A
GE HealthCare to acquire Sofie Biosciences for $945M
BioPharma Dive
β†’
Product Launch
Abbott launches SimpleScreen CRC blood-based colorectal cancer screening test in the US
Fierce Biotech
β†’
October 5, 2026
M&A
Shionogi acquires Texas-based rare disease biotech IntraBio for $2B
BioPharma Dive
β†’
Regulatory
Click Therapeutics wins FDA clearance for Motivista, first digital therapeutic for schizophrenia negative symptoms
Fierce Biotech
β†’
September 17, 2026
Regulatory
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
CancerNetwork
β†’
September 18, 2026
Regulatory
FDA approves Inluriyo (imlunestrant) + Verzenio combination for ER+ HER2- ESR1-mutated metastatic breast cancer
Eli Lilly
β†’
October 2, 2026
Regulatory
FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
Fierce Pharma
β†’
September 18, 2026
M&A
Novo acquires 3 early-stage obesity drug programs from Kallyope
Fierce Biotech
β†’
September 18, 2026
Regulatory
FDA Accepts IntraBio's sNDA for Levacetylleucine (AQNEURSA) for Ataxia-Telangiectasia with Priority Review
NeurologyLive
β†’
September 30, 2026
M&A
Lundbeck reportedly seeks to acquire US pharma company Xeris Biopharma
medwatch.com
β†’
September 28, 2026
Layoffs
BioNTech to close 3 German sites after failed buyer search, ~1,800 jobs impacted
Fierce Pharma
β†’
October 1, 2026
Layoffs
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Fierce Biotech
β†’
September 30, 2026
Product Launch
Scholar Rock secures FDA approval for SMA treatment apitegromab (Isembyld)
fiercepharma.com
β†’
September 29, 2026
M&A
AVS Bio acquires Cambridge life sciences firm Biorbyt
Business Weekly
β†’
September 21, 2026
M&A
Bayer sells cancer drug Stivarga to GrΓΌnenthal for up to $431M
Fierce Pharma
β†’
September 21, 2026
Regulatory
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
HCPLive
β†’
September 22, 2026
Regulatory
FDA approves Zanvastro, first drug to treat Alexander disease, developed by Ionis Pharmaceuticals
Medical Xpress
β†’
September 22, 2026
Layoffs
BMS lays off 265 New Jersey staff amid ongoing reorganization
PharmaLive
β†’
September 22, 2026
Layoffs
Bristol Myers cuts another 265 jobs tied to New Jersey headquarters
Fierce Pharma
β†’
September 27, 2026
Regulatory
Mirum Pharmaceuticals Wins FDA Approval for Atebrioz for Rare Bone Disorder FOP
MedCity News
β†’
September 22, 2026
Regulatory
FDA Approves Lantheus' Bravnetsa (Lu 177 Dotatate) for GEP-NETs
Oncology Nursing News
β†’
September 23, 2026
Regulatory
FDA Approves Elevar Therapeutics' Lirafugratinib for FGFR2+ Cholangiocarcinoma
Oncology Nursing News
β†’
September 24, 2026
Regulatory
FDA Approves Eli Lilly's Once-Weekly Basal Insulin Onswik for Type 2 Diabetes
Pharmaceutical Executive
β†’
September 25, 2026
Regulatory
FDA Approves Zilurgisertib (Atebrioz) for FOP in Patients 12 and Older
hcplive.com
β†’
M&A
Lexeo acquires Mantle Therapeutics for $8.3M upfront to expand Friedreich ataxia pipeline
Fierce Biotech
β†’
IPO
ADARx scores upsized $446M IPO; City Therapeutics maps out Nasdaq plans
Fierce Biotech
β†’
September 17, 2026
Regulatory
FDA Clears Neptune Medical's Triton 1 Robotic Endoscopy System for Colon Procedures
CancerNetwork
β†’
September 24, 2026
M&A
ITM Isotope Technologies Munich SE merges with Telix Pharmaceuticals in $2.35B radiopharma deal
ICLG
β†’
September 24, 2026
M&A
Eli Lilly acquires 5-MeO-DMT developer AtaiBeckley for up to $3.8B
Healthcare Brew
β†’
September 22, 2026
Layoffs
Novo Nordisk workforce reduction reaches 13,000 amid R&D restructuring
BioSpace
β†’
September 23, 2026
Regulatory
FDA advisory panel recommends approval of Grail's multi-cancer blood test Galleri
NPR
β†’
IPO
Inflammation biotech Electra raises $350M in upsized Nasdaq IPO
Fierce Biotech
β†’
September 18, 2026
IPO
Electra raises $350M in IPO, testing appetite for clinical-stage biotech
biopharmadive.com
β†’
September 21, 2026
M&A
Telix to Acquire ITM in $1.65B Radiopharmaceutical Merger
BioPharm International
β†’
IPO
Iambic Therapeutics files for IPO, prioritizing HER2 inhibitor IAM1363
Fierce Biotech
β†’
September 21, 2026
M&A
Xenetic to acquire Santersus in all-stock NET-targeting biotech combination
AllSci
β†’
IPO
TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
Fierce Biotech
β†’
September 21, 2026
M&A
Telix Acquires ITM in $1.65B Radiopharmaceutical Deal
MedCity News
β†’
September 16, 2026
Regulatory
FDA issues warning letter to Bausch & Lomb over aseptic processing failures at Tampa plant
BioSpace
β†’
September 19, 2026
Regulatory
Ultragenyx Gene Therapy Fayuvi Receives FDA Approval for Sanfilippo Syndrome
MedCity News
β†’
Funding
BrainChild Bio raises $116M Series A for CAR-T therapies
Fierce Biotech
β†’
September 8, 2026
Regulatory
Sandoz CEO warns of Trump's generic drug tariff impact
CNBC
β†’
M&A
Labcorp acquires MLM Medical Labs to expand global laboratory footprint
Fierce Biotech
β†’

Get biotech signals in your CRM

We monitor FDA decisions, trial readouts, funding, and M&A across your target accounts. Signals land in your CRM linked to the right contacts β€” your reps act on them the same morning.

Book a 15 min call
Dominykas Rukas - Revenanas

Start scaling with systems, not headcount

Book a call
Dominykas Rukas - Revenanas
BlogServicesAbout usCustomer testimonials
Revenue auditMarket newsSignals hubClay ConsultingClay Resources
linkedin icon
Β©2025, Revenanas
Privacy Policy
Cookies Settings